Pharming Group (NASDAQ:PHAR) Stock Price Up 4.3%

Shares of Pharming Group (NASDAQ:PHAR) traded up 4.3% during mid-day trading on Wednesday . The stock traded as high as $8.05 and last traded at $8.05. 483 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 3,677 shares. The stock had previously closed at $7.72.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Friday, May 31st.

Pharming Group Stock Performance

The firm’s 50-day simple moving average is $9.05 and its 200 day simple moving average is $10.66.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.20). The business had revenue of $55.59 million for the quarter, compared to analyst estimates of $68.43 million. Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. Equities research analysts anticipate that Pharming Group will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC bought a new stake in Pharming Group (NASDAQ:PHAR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is currently owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.